
Citation:

Webb, BA and Cheah, LT and Khalil, JS and Hindle, MS and McKay, M and Turner, NA and Kearney, MT and Ariens, RAS and Duval, C and Naseem, KM (2025) The critical role of platelet adenylyl cyclase 6 in haemostasis and thrombosis. *Journal of Thrombosis and Haemostasis*. ISSN 1538-7836 DOI: <https://doi.org/10.1016/j.jtha.2025.02.045>

Link to Leeds Beckett Repository record:

<https://eprints.leedsbeckett.ac.uk/id/eprint/12093/>

Document Version:

Article (Published Version)

Creative Commons: Attribution 4.0

The aim of the Leeds Beckett Repository is to provide open access to our research, as required by funder policies and permitted by publishers and copyright law.

The Leeds Beckett repository holds a wide range of publications, each of which has been checked for copyright and the relevant embargo period has been applied by the Research Services team.


We operate on a standard take-down policy. If you are the author or publisher of an output and you would like it removed from the repository, please [contact us](#) and we will investigate on a case-by-case basis.

Each thesis in the repository has been cleared where necessary by the author for third party copyright. If you would like a thesis to be removed from the repository or believe there is an issue with copyright, please contact us on openaccess@leedsbeckett.ac.uk and we will investigate on a case-by-case basis.

Journal Pre-proof

The critical role of platelet adenylyl cyclase 6 in haemostasis and thrombosis

Beth.A. Webb, Lih.T. Cheah, Jawad.S. Khalil, Matthew.S. Hindle, Mary McKay,
Neil.A. Turner, Mark.T. Kearney, Robert.A.S. Ariens, Cedric Duval, Khalid.M. Naseem



PII: S1538-7836(25)00188-6

DOI: <https://doi.org/10.1016/j.jtha.2025.02.045>

Reference: JTHA 1007

To appear in: *Journal of Thrombosis and Haemostasis*

Received Date: 6 November 2024

Revised Date: 21 February 2025

Accepted Date: 26 February 2025

Please cite this article as: Webb BA, Cheah LT, Khalil JS, Hindle MS, McKay M, Turner NA, Kearney MT, Ariens RAS, Duval C, Naseem KM, The critical role of platelet adenylyl cyclase 6 in haemostasis and thrombosis, *Journal of Thrombosis and Haemostasis* (2025), doi: <https://doi.org/10.1016/j.jtha.2025.02.045>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.

The critical role of platelet adenylyl cyclase 6 in haemostasis and thrombosis

Beth. A. Webb¹, Lih. T. Cheah¹, Jawad. S. Khalil¹, Matthew. S. Hindle^{1,*}, Mary McKay¹, Neil. A. Turner¹, Mark. T. Kearney¹, Robert. A.S. Ariens¹, Cedric Duval¹ and Khalid. M. Naseem¹.

¹ Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

* Current address - Centre for Biomedical Science Research, Leeds Beckett University, Leeds, UK

Article type: original article

Running head: AC6 mediates haemostasis and thrombosis.

Author for correspondence: Khalid M Naseem, Leeds Institute of Cardiovascular & Metabolic Medicine, the LIGHT Laboratories, Clarendon Way, University of Leeds, Leeds LS2 3AA

Tel: +44 (0)1133431560

E-mail: k.naseem@leeds.ac.uk

Abstract word count: 250

Word count (excluding figure legends and references): 4713

Total number of references: 72

Figure count: 5

Supplementary figure count: 9

Table count: 1

Abstract:

Background: Platelet activation is constrained by endothelial-derived prostacyclin (PGI₂) through cyclic adenosine-5'-monophosphate (cAMP) signalling involving multiple isoforms of adenylyl cyclase (AC). The roles of specific AC isoforms in controlling haemostasis remain unclear and require clarification.

Objectives: To understand the specific contribution of AC6 in platelet haemostatic and thrombotic function.

Methods: A platelet-specific AC6 knockout (AC6-KO) mouse was generated. Biochemical approaches were used to determine intracellular signalling, with flow cytometry, tail bleeding time assays and *in vivo* thrombosis by ferric chloride were used to measure the haemostatic and thrombotic importance of platelet AC6.

Results: Loss of AC6 resulted in diminished accumulation of platelet cAMP in response to PGI₂, while basal cAMP was unaffected. We found no differences in phosphodiesterase 3A (PDE3A) activity, suggesting the defect was in generation rather than hydrolysis of cAMP. Consistent with this, phosphorylation of PKA substrates, vasodilator-stimulated phosphoprotein and glycogen synthase kinase were diminished but not ablated. Functional studies demonstrated that the inhibition of thrombin-induced fibrinogen binding and P-selectin expression by PGI₂ was severely compromised, while inhibition of GPVI-mediated platelet activation was largely unaffected. Under conditions of flow formed stable thrombi, but in the absence of AC6, thrombi were insensitive to PGI₂. *In vivo* diminished sensitivity to PGI₂ manifested as significantly reduced tail bleeding and accelerated occlusive arterial thrombus formation in response to vascular injury that were highly unstable and prone to embolisation in AC6-KO mice.

Conclusions: These data demonstrate that AC6 is linked directly to PGI₂-mediated platelet inhibition and regulation of haemostasis and thrombosis *in vivo*.

Keywords: platelets, adenylyl cyclase 6, cAMP, PKA, thrombosis, haemostasis.

Introduction:

Crosstalk between endothelial-derived mediators, such as prostacyclin (PGI₂) and nitric oxide (NO) and platelets, is critical to the control of haemostasis [1-7]. PGI₂ is the more potent of these two inhibitors based on the much higher expression of the downstream signalling apparatus and effectors [8]. In circulation, the marginalisation of platelets during blood flow facilitates their continual exposure to PGI₂, ensuring they remain inactive. Ligation of the prostaglandin I₂ (IP) receptor by PGI₂ is coupled to a complex system involving enzymes and adaptors that facilitate the generation, propagation, and termination of 3',5'-cyclic adenosine monophosphate (cAMP) signalling. The binding of PGI₂ to the IP receptor activates membrane adenylyl cyclase (AC) through Gα_s and G protein-coupled receptors (GPCR), resulting in elevations in cAMP and activation of protein kinase A (PKA) isoforms. The subsequent phosphorylation of a plethora of key protein substrates results in the inhibition of multiple aspects of platelet function [9]. Increased platelet cAMP is associated with reduced Ca²⁺ mobilisation, dense granule secretion, integrin α_{IIb}β₃ activation and aggregation *in vitro* [10], and reduced platelet accrual at sites of vascular injury *in vivo* [11]. However, much of the data regarding the role of cAMP in platelet function has been gained from *in vitro* studies, using cAMP mimetics that act as global cAMP modulators or bypass AC, as well as pharmacological inhibitors that have consistently been shown to have off-target effects [12]. Consequently, a precise understanding of the relationship between specific AC and PKA isoforms, individual substrates/signalling targets, and the distinct platelet functions highlighted above is still lacking.

Seminal gene deletion studies demonstrated that loss of the IP receptor led to a prothrombotic phenotype confirming PGI₂ as a key regulator of thrombosis *in vivo* and are supported by clinical studies suggesting impaired cAMP in subjects with acute coronary syndromes (ACS) [13-15]. However, our understanding of how cAMP signalling controls platelet function through a myriad of signalling enzymes and where the systems fail in atherothrombotic disease is unclear. Dissecting the functionality of the pathway downstream of the IP receptor has been hampered by a lack of pharmacological tools and genetic models [16]. The precise role of PKA isoforms has proved difficult because the deletion of PKA regulatory subunits is either embryonically lethal [17, 18] or results in compensation through upregulation of other subunits [17, 19]. Given this complexity, and as a first step to understanding the role of different components of the cAMP systems, we focussed our attention on the roles of AC. This first step in the pathway has recently been shown to be critical in ACS where dysfunctional AC activity is linked to reduced efficacy of P2Y₁₂ receptor antagonists [20].

The soluble AC isoform, AC9, was shown to be the most dominant isoform in mice with a copy number of ~2493 [21, 22], however, because this isoform is not expressed in human platelets, we decided to focus our efforts on isoforms expressed in both human and murine platelets. Further studies indicate that AC6 is highly expressed in both human and murine platelets with a copy number of ~2166 in mice [21] and ~2500 in humans [23], with significantly lower expression of AC3 (human) and AC5 (murine), respectively [21-24]. The reason for multiple AC isozymes in platelets is unclear, and to explore the possibility that AC in platelets play functionally distinct roles we generated a platelet-specific deletion of AC6. Our data demonstrate that AC6 is responsible for selective inhibition of platelet activation and plays a central role in controlling haemostasis and thrombosis in mice.

Materials and methods:**Reagents**

PAR4 peptide (Anaspec), CRP-XL (CambCol Laboratories), PGI₂ and Forskolin (Cayman Chemical), Amersham cAMP Biotrak Enzymeimmunoassay (EIA) system (Cytiva), S-Nitrosoglutathione (GSNO), 8-CPT-cAMP and Mouse Anti-Adenylate cyclase (sc-377243) (Santa Cruz Biotechnology), SQ22537 (Calbiochem), Annexin V APC ready flow conjugate, Fast RNA extraction with PureLink RNA Mini Kit (Invitrogen), phospho-VASP^{Ser239} (3114), phospho-VASP^{Ser157} (3111), phospho-PKA Substrate (RRXS*/T*) (9624), phospho-GSK3 β ^{Ser9}, GAPDH (2118) (Cell Signalling Technologies), BD Phosflow Lyse/Fix Buffer 5X, FITC Rat IgG1 λ isotype control (553995), FITC Rat Anti-mouse CD62P (553744), BB700 Rat Anti-mouse CD41 (742148), FITC Hamster Anti-rat CD49b (554999), FITC Hamster IgG1 κ Isotype control (553971), FITC Rat Anti-mouse CD41 (553848), FITC Rat IgG1 κ isotype control (553924), FITC Hamster Anti-mouse CD61 (553346), and FITC Hamster IgG1 κ isotype control (553971) (BD Biosciences), PE Rat Anti-mouse Integrin α IIb β 3 (M023-2), FITC Rat Anti-mouse GP1b α (M040-1), FITC Rat Anti-mouse integrin α 2 (M071-1), FITC Rat Anti-mouse GPVI (M011-1), FITC Rat IgG Polyclonal (P190-1) and PE Rat IgG Polyclonal (P190-2) (Emfret), Anti-phospho-PDE3A^{Ser312} and Anti-PDE3A (MRC-PPU, University of Dundee), Collagen Reagents HORM® suspension (Takeda), Restore™ Western Blot Stripping buffer, SuperSignal West Pico Plus Pierce™ ECL, TaqMan™ primers (Adcy6: Mm00475773_g1, Adcy5: Mm00674122_m1, Adcy3: Mm00460371_m1 and Gapdh: Mm99999915_g1) and TaqMan™ Fast Advanced Master Mix (Thermo Fisher Scientific), Reverse Transcription System (Promega). All other reagents were from Sigma-Aldrich.

Experimental animals

All animal husbandry, housing and procedures were carried out in line with the regulations and guidelines of the University of Leeds Central Biological Services facility under the Animals (Scientific Procedures) Act 1986 and carried out under United Kingdom Home Office approved project licences (PP0499799 and PP9539458). Animals received standard rat and mouse no.1 maintenance diet (RM1, Special Diet Services) and water by Hydropac pouches. All mice were housed in individually ventilated cages (GM500, Techniplast), with 12 hours of light/dark cycles, at 21°C and 50-70% humidity.

PF4-cre⁺/Adcy6^{fl/fl} experimental mice were generated via a Cre-lox approach by crossbreeding Adcy6^{fl/fl} (RRID:IMSR_JAX:022503) and PF4-cre⁺ (RRID:IMSR_JAX:008535) mice purchased from the Jackson Laboratory (Bar Harbour, ME, USA). Homozygous female Adcy6 floxed mice were bred with Hemizygous male mice expressing Cre recombinase under the control of the Platelet Factor 4 (PF4) promoter generating heterozygous floxed Adcy6 and hemizygous PF4-cre. Male mice hemizygous for PF4-cre and heterozygous for floxed Adcy6 were bred with females heterozygous for floxed Adcy6. This yielded animals homozygous for floxed Adcy6 with and without PF4-cre. Mice with PF4-cre expression have platelet-specific KO of Adcy6, while mice without PF4-cre function as littermate controls. Throughout this study, PF4-cre⁺/Adcy6^{fl/fl} are denoted as AC6-KO and Adcy6^{fl/fl} littermate controls are denoted as WT. All mice generated were on a C57Bl/6 background and both male and female mice were used throughout this study. Prior to use, all pups were ear notched at weaning (~3 weeks of age) to allow for identification and isolation of genomic DNA (gDNA) for automated genotyping by Transnetyx.

mRNA expression, flow cytometry, immunoblotting, cAMP measurement, *in vitro* flow and *in vivo* thrombosis

Detailed methods are described in the supplemental methods.

Statistics

Results are expressed as means \pm SD unless otherwise stated and statistical analyses were performed using GraphPad Prism 9.0 (La Jolla, CA). Comparisons between WT and AC6-KO were performed by two-way ANOVA with Šídák's multiple comparisons post-hoc test unless otherwise stated and statistical significance was accepted at $p < 0.05$.

Data sharing statement

All raw data and protocols can be made available by emailing the corresponding author.

Journal Pre-proof

Results:

Establishment of the platelet-specific AC6-knockout mouse

The novel platelet-specific AC6-KO mouse was generated using the PF4 promoter to ensure the AC6 gene was deleted in cells of the megakaryocyte lineage (Figure 1A). To confirm the platelet specificity of the AC6-KO mouse, we tested the mRNA levels of the AC6 gene (*Adcy6*) in WT and AC6-KO platelets using real-time q-PCR. AC6 was successfully deleted in platelets (Figure 1B) but not in other tissues (e.g. heart and kidney) (Suppl. Figure 1), confirming that the deletion of AC6 is restricted to the platelet-megakaryocyte lineage (Figure 1B). This was confirmed via immunoblotting using a pan-AC antibody, whereby total AC protein expression was unchanged in WT vs AC6-KO in heart and kidney (Suppl. Figure 2). Further, we observed no change in the expression of AC9 and AC5, and consistent with other studies, we found no expression of AC3 in murine platelets [21, 24] (Figure 1B). Immunoblotting for total AC showed a significantly reduced protein expression in platelets, with residual protein likely to be the remaining AC5 and AC9 (Figure 1C). Importantly, we observed no change in PDE3A and PDE2A mRNA expression in WT and AC6-KO platelets (Suppl. Figure 3). In addition, we found no changes in protein expression of key components of the cAMP signalling system, including phosphodiesterase 3A (PDE3A) (Figure 2C), vasodilator-stimulated phosphoprotein (VASP) (Suppl. Figure 4) and key PKA subunits (Suppl. Figure 5). Importantly, we observed no difference in haematological blood parameters between WT and AC6-KO (Table 1). Analysis of the platelets from AC6-KO mice and littermate controls showed no major differences in the expression of key platelet receptors (Suppl. Figure 5A). Further, platelet numbers drawn from CD42b positive cells and young reticulated platelets from Thiazole Orange positive events showed no difference between WT and AC6-KO platelets (Suppl. Figure 5B & C), suggesting that platelet counts and turnover were similar in both groups of mice.

Contribution of AC6 to platelet cAMP production and PKA-mediated phosphorylation events

We first investigated the role of AC6 in platelet cAMP synthesis using a cAMP assay. Basal cAMP generation was unchanged between WT (303 ± 161 fmol/ 10^7 platelets) and AC6-KO (224 ± 65 fmol/ 10^7 platelets) mice. Treatment of platelets with PGI₂ (0-100 nM, 30s) led to a concentration-dependent increase in cAMP in WT platelets, while in AC6-KO platelets, cAMP synthesis was severely compromised (Figure 2A). In response to PGI₂ (100 nM) there was a 77.6% reduction in cAMP formation in AC6-KO compared to WT platelets (8860 ± 2699 to 1984 ± 417 fmol/ 10^7 platelets, $p < 0.0001$). When cAMP synthesis was assessed as a function of time, we found that its generation was severely delayed in AC6-KO platelets; at 1 minute, the levels were 8682 ± 1896 fmol/ 10^7 platelets (WT) and 4385 ± 1175 fmol/ 10^7 platelets (AC6-KO) (Figure 2B). Importantly, we found that in the absence of AC6, platelets retained some capacity to produce cAMP. Since cAMP concentrations are synergistically linked to synthesis and hydrolysis, we examined the potential role of PDE3A, the enzyme responsible for breaking down cAMP in platelets [25]. We observed no changes in the expression or activity of PDE3A between WT and AC6-KO platelets (Figure 2C and 2D).

Given the reduced cAMP generation, we next examined the importance of AC6 in cAMP-mediated, PKA phosphorylation events, using established platelet PKA substrates. In both groups, PGI₂ (1-100 nM) caused a concentration-dependent increase in phosphoVASP^{Ser157}, phosphoVASP^{Ser239}, phosphoGSK3 β ^{Ser9} (Figure 3), and phosphoPDE3A^{Ser312} (Suppl. Figure 7). The phosphorylation of VASP^{Ser157}, VASP^{Ser239} and GSK3 β ^{Ser9} was reduced in AC6-KO platelets at all concentrations of PGI₂ but not abolished (Figure 3A). While phosphorylation of PDE3A^{Ser312} appeared to be slightly reduced in the AC6-KO, this was not significant (Suppl. Figure 7A-B).

We then applied forskolin (0.1-10 μ M), which directly activates AC 1-8 (excluding AC9) to produce cAMP in a non-compartmentalised manner, independent of the IP receptor. Consistent with reduced capacity for cAMP generation, we found compromised phosphorylation of VASP^{Ser157}, VASP^{Ser239} and GSK3 β ^{Ser9}, but with little effect on PDE3A^{Ser312} phosphorylation (Figure 3B and Suppl. Figure 7C-D). To assess cAMP production via receptors independent from the IP receptor, we measured VASP^{Ser157} phosphorylation in response to adenosine (100 μ M). Consistent with our findings in response to PGI₂, we found that VASP^{Ser157} phosphorylation was impaired to basal levels in the AC6-KO compared to WT platelets ($p < 0.01$) (Suppl. Figure 8). To confirm that the cAMP signalling apparatus downstream of AC6 was unaffected, we treated platelets with the non-hydrolysable analogue of cAMP, 8-CPT-cAMP (1-100 μ M), and we observed no differences in the phosphorylation of VASP^{Ser157} between WT and AC6-KO (Figure 3C). Using phosphoflow cytometry [26, 27] we found that platelets from AC6-KO mice produced significantly less phosphorylation of VASP^{Ser157} and VASP^{Ser239} than WT mice when stimulated with PGI₂ (100 nM) (16.9 ± 5.1 WT versus 11.9 ± 3.7 AC6-KO fold increase over basal phosphoVASP^{Ser239}; $p < 0.05$) (Figure 3D), confirming that cAMP signalling is also compromised in whole blood.

Loss of AC6 leads to selective platelet hyposensitivity to PGI₂

We next assessed whether AC6 was linked to multiple platelet functions in the physiological conditions of whole blood. We investigated the functional consequences using flow cytometric analysis of the key surface markers of platelet activation, active integrin $\alpha_{IIb}\beta_3$ (JON/A) and P-selectin (CD62P). We observed no difference in the ability of CRP-XL (1 μ g/mL; Figure 4C) or PAR4 peptide (100 μ M) to increase the surface expression of CD62P or active $\alpha_{IIb}\beta_3$ (data not shown). When whole blood was treated with PGI₂ (1-100 nM) before the addition of PAR4 peptide (100 μ M) or CRP-XL (1 μ g/mL) or we observed a concentration-dependent inhibition of both markers in WT mice (Figure 4A-B). At 5 nM of PGI₂, we observed almost complete inhibition of both surface markers in WT platelets. However, in AC6-KO platelets, we found that the ability of PGI₂ to inhibit PAR4 peptide-stimulated P-selectin expression and activated $\alpha_{IIb}\beta_3$ were significantly impaired (Figure 4A). For example, at PGI₂ (5 nM), we found $75 \pm 14\%$ inhibition of P-selectin expression in WT platelets compared to $16 \pm 5\%$ inhibition in AC6-KO platelets ($p < 0.0001$). To examine another pathway of platelet activation, we considered procoagulant activity, here activated platelets facilitate coagulation by exposing procoagulant phosphatidylserine (PS) on their outer surface. In separate experiments, we assessed the inhibition of PS exposure by PGI₂ upon CRP-XL alone and dual agonist stimulation with PAR4 peptide and CRP-XL. Consistent with earlier experiments, PGI₂ inhibited CRP-XL-stimulated Annexin V binding to procoagulant PS in both AC6-KO and WT mice (Figure 4C). Dual stimulation with CRP-XL/PAR4 peptide led to increased PS exposure compared to CRP-XL alone, but here we observed a significant reduction in PS expression in response to PGI₂ in WT but not AC6-KO platelets (Figure 4C).

We next examined how the impaired cAMP signalling in AC6-KO platelets affected function. Measurement of static platelet adhesion showed that AC6-KO platelets adhered normally to both fibrinogen and collagen (Figure 4D). While it was not significantly different between WT and AC6-KO under direct comparison, the inhibitory actions of PGI₂ were compromised in the AC6-KO mice (Figure 4D). The number of WT platelets adhering to fibrinogen decreased from 45.7 ± 2.6 per field of view (FoV) to 14.8 ± 5.6 per FoV in the presence of PGI₂ (10 nM) ($p < 0.05$), whereas AC6-KO platelets only displayed a slight reduction from 38.8 ± 6.7 per FoV to 28.2 ± 5.7 per FoV in the presence of PGI₂ (10 nM) (Figure 4D). In contrast, platelet adhesion to collagen was significantly reduced in the presence of PGI₂ (10 nM) in both WT and AC6-KO platelets (Figure 4D). Taken

together, these data suggest that AC6 may play a role in inhibiting platelet adhesion to fibrinogen, but not to collagen. To examine the consequences of platelet AC6 deletion on thrombus formation under flow we perfused (1000s^{-1}) whole blood from AC6-KO and WT over immobilised fibrinogen (1 mg/mL). Under these conditions, platelets from both AC6-KO and WT mice adhered to the fibrinogen to form a series of microaggregates with no differences in overall surface coverage (Figure 4E). Preincubation of the blood from WT mice with PGI_2 (50 nM) led to a significant reduction in surface area coverage ($7.1\pm1.5\%$ to $3.0\pm1.5\%$, $p=0.0005$). In contrast, PGI_2 did not affect platelet adherence and recruitment to fibrinogen in AC6-KO mice (Figure 4E & Suppl. Figure 9).

AC6 controls haemostasis, thrombosis, and thrombus stability

Platelet aggregation and adhesion are critical to haemostasis *in vivo*, and our *in vitro* and *ex vivo* observations suggested that AC6-KO mice could be prone to accelerated thrombus formation due to PGI_2 hyposensitivity. To test this hypothesis, we first evaluated bleeding time using tail clip assays (Figure 5A). Here AC6-KO mice exhibited a significantly reduced bleeding time compared to WT mice, with bleeding time reduced from 228 ± 91 seconds for WT mice to 99 ± 62 seconds for AC6-KO mice ($p=0.005$). Effective haemostasis is reliant upon the efficient formation of stable thrombi, and therefore we examined *in vivo* thrombus formation in response to ferric chloride (FeCl_3)–induced injury to mesenteric arterioles using fluorescence microscopy. Following FeCl_3 treatment, we found the rate of thrombosis was accelerated in the absence of AC6 (Figure 5B and 5C) as evidenced by a significantly reduced occlusion time from 25.33 ± 4.90 to 19.16 ± 4.30 minutes ($p=0.007$). (Figure 5B). Further, we found that the area of the thrombus formed post-injury was significantly bigger in AC6-KO mice (Figure 5D). While observing thrombosis *in vivo*, we noticed that the thrombi formed were less stable. To examine this we conducted individual kinetic analysis on thrombi by assessing sudden loss of fluorescence, a method we have used previously to measure embolisation [28]. Embolic events were defined as a loss in thrombus area greater than 15% between time points. We observed a 3.5-fold increase in the total number of embolic events in AC6-KO mice compared to WT mice (Figure 5E and 5F) (Welch's t-test, $p=0.04$), suggesting a reduction in thrombus stability in the AC6-deficient mice.

Discussion:

The tonic inhibition of platelets through endothelial-derived PGI_2 is critical to the effective management of systemic haemostasis. However, our understanding of the complex signalling events that allow cAMP to control platelets and the contribution of key signalling nodes has remained elusive, primarily due to a lack of precise pharmacological and genetic tools. In this study, we generated a model to study AC6 mediated-cAMP signalling in platelets and show that AC6 is critical to haemostasis in mice while also highlighting potential redundancy in this signalling system. In our novel platelet-specific AC6-KO mouse we found that the deletion of the *Adcy6* gene from the megakaryocyte lineage had no effect on platelet numbers and morphology but did reveal that (i) AC6 is linked to PGI_2 -induced cAMP generation and downstream PKA signalling, (ii) AC6 generated cAMP is selectively coupled to the inhibition of PAR-mediated platelet activation, and (iii) AC6-KO mice have an aggressive prothrombotic phenotype that is associated with reduced bleeding times despite the presence of other AC isoforms.

Our first key observation was that the loss of AC6 does not affect 'basal' cAMP generation in washed platelets *in vitro* in the absence of exogenous stimulation of the IP receptor/AC by PGI_2 . Consistent with other studies

[30, 31], this suggests that *in vitro*, the residual AC activity is relatively small compared to *in vivo* studies and could suggest AC5 or soluble AC9 may control unstimulated cAMP production, as suggested for other cells [32, 33]. In contrast, AC6-KO platelets exhibited impaired PGI₂-mediated cAMP production, with both amount and rate of cAMP accumulation were diminished but not ablated. We confirmed that the reduced accumulation of cAMP was linked to synthesis rather than accelerated hydrolysis since there was no significant change in the expression of PDE3A and PDE2, or PDE3A activity, [15, 34, 35]. It has been well-established that platelet PDE3A activity is essential to maintain low equilibrium levels of cAMP and to determine a threshold for platelet activation [35, 36], which could account for a lack of PDE3A compensation in our AC6-KO mouse. These data suggest for the first time a potential redundancy between AC isoforms in platelets, and while the IP receptor is coupled to AC6, it must also be linked to other cAMP-generating enzymes. Mirroring the impaired cAMP production in the absence of AC6, there was diminished phosphorylation of established PKA substrates, VASP [37-41] and GSK [42]. The loss of signalling in the AC6-KO was not linked to changes in the expression of PKA regulatory or catalytic subunits. Furthermore, a loss of AC6 also significantly impaired adenosine-driven cAMP signalling as measured by VASP^{Ser157} phosphorylation, suggesting that AC6 activity may be localised to multiple cAMP-generating receptors.

The most relevant cell model to platelets are vascular smooth muscle cells (VSMCs), which share many features of cAMP signalling, including PKA isoforms and their known protein targets (VASP, IP3R1 and MYPT1). Among the AC isoforms expressed in VSMCs, AC3, AC5, and AC6 are the most prominent [43-47]. While studies have shown that AC6, in particular, is coupled to β -adrenergic receptors (β AR)-mediated signalling, the precise coupling of IP to specific AC isoforms requires further investigation though it is plausible given its regulatory role in cardiac muscle [47] and our own observations, that AC6 may be involved in IP signalling in VSMCs [46, 48]. In endothelial cells, ACs play a role in vascular permeability. It was found that prostacyclin-mediated signalling via AC6 (not AC5) contributed to a feedback loop that increases barrier function. Confirmed in HUVECs by adenoviral gene transfer of AC6 not AC5 led to an increase in IP receptor-stimulated cAMP, while thrombin-stimulated increases in endothelial cell barrier function were reduced [49]. While beyond the scope of the current study, further investigation into the specific roles of platelet AC5, AC6 and soluble AC9 are warranted.

Interestingly, we found that cAMP-mediated phosphorylation of PDE3A^{Ser312} [35] and PDE3A activity was unaffected by loss of AC6. We believe this is an important observation since it suggests for the first time that specific targets for PKA-mediated phosphorylation could be linked to distinct cAMP-generating systems. PDE3A can be phosphorylated and activated by Protein Kinase C (PKC) independently of PKA activity [50, 51]. We have shown that in the absence of AC6, cAMP levels are reduced in response to PGI₂, with impaired PGI₂-mediated inhibition of PAR-stimulated platelet activity. It is well known that Thrombin and protease-activated receptor peptides (SFLLRN and GYPGKF) activate PDE3A through PKC, thus increasing cAMP hydrolysis [35]. Our findings demonstrate that a loss of AC6 thereby tips the balance between cAMP generation and hydrolysis, resulting in impaired PGI₂-mediated inhibition of PAR-stimulated platelet activity. The lack of a phenotype in response to inhibition of GPVI-mediated platelet activity by PGI₂ indicates a potential role for novel PKC isoforms PKC δ or PKC θ , which have positive regulatory roles in PAR-stimulated responses but negative roles in GPVI signalling [51-54].

To understand the ability of AC6 to control platelet function, we focussed on studies with whole blood. Using phosphoflow, we were able to establish that PGI₂ is active in whole blood and able to induce cAMP signalling in platelets, which was diminished but not abolished by the absence of AC6. We next moved through a series of progressively more physiological assays to pinpoint how diminished cAMP affects platelet function. Flow cytometry demonstrated that platelet activation was unaffected by the loss of the enzyme, which we believe is consistent with our observation that basal cAMP remains unaffected, as well as other studies in IP receptor-null mice, whereby thrombosis was accelerated while platelet aggregation remained normal [30]. However, we did find that the ability of PGI₂ to inhibit PAR-stimulated platelet activity was severely compromised, while GPVI-mediated activation was unaffected [55, 56]. We know that our observations demonstrate that AC6-generated cAMP is not linked to all GPCRs since inhibition of U46619- and ADP-mediated platelet aggregation were also unaffected by AC6 deficiency (data not shown). The reason for this is unclear but is consistent with earlier studies demonstrating that early GPVI signalling is unaffected by cAMP signalling [57]. Previously, we demonstrated that cAMP signalling prevents thrombin-induced membrane compartmentalisation of RhoA [58]. This finding could explain why the PGI₂ signalling defect observed in AC6-KO platelets is observed more prominently in PAR- and GPVI-mediated pathways. Interestingly, when we examined static platelet adhesion, inhibition of fibrinogen-mediated adhesion by PGI₂ was compromised in AC6-KO but not in WT platelets, while inhibition of collagen-mediated adhesion was unchanged between the two genotypes. In many nucleated cells, cAMP signalling is partitioned to restrict signalling to intended targets and allows concurrent signals to drive specific functions [59]. We have shown previously that a similar system may exist in platelets, where anchored PKA is responsible for controlling, at least in part, signalling downstream of GPIb [60]. Therefore, the inhibition of GPVI-mediated activation may be linked specifically to a distinct isoform of AC, potentially AC5 or AC9, although this would require significant further investigation to establish. Nevertheless, we did find that the loss of AC6 severely compromised the ability of PGI₂ to inhibit *in vitro* thrombosis to immobilised fibrinogen, suggesting that the AC6 may be important in thrombosis. Indeed, we show that despite the absence of AC6 not fully blocking cAMP synthesis and signalling, it has a profound effect on haemostasis and thrombosis *in vivo*. We found significantly reduced bleeding times in tail clip assays, which was coupled to a more aggressive and rapid thrombotic response to vascular injury. Interestingly, the thrombi formed *in vivo* in the AC6 deficient mice were inherently unstable, which may suggest potential problems with the speed of platelet deposition, fibrin generation or clot retraction. Taken together, we propose that the diminished bleeding time is related to accelerated thrombosis in the absence of AC6. This is likely due to a reduced downstream effect of PGI₂ in controlling thrombosis. While it is difficult to measure platelet sensitivity to PGI₂ *in vivo* because of the constant production and release by the endothelium, its short half-life and the presence of platelet PDEs, we believe that other pieces of evidence point to this being a probable explanation. Firstly, the reduced inhibitory effect of PGI₂ on whole blood *ex vivo* thrombosis and secondly, the diminished PKA signalling events measured by phosphoflow in whole blood. The nature of the hyperthrombotic response is likely multifactorial including unchecked platelet secretion and pro-coagulant function supported by our flow cytometry findings. The increased generation of procoagulant platelets leads to exposure of PS on their surface to support the formation of both tenase and prothrombinase complexes required for thrombin and fibrin generation. Potent platelet activation leads to the generation of two core subpopulations that may enact distinct functional roles, and we have previously shown that PGI₂ plays a key role in modifying these subpopulations in whole blood and, in particular, preventing PS exposure at the cell surface [26]. Our observation that in the absence of AC6, the ability of PGI₂ to modulate PS in response to dual stimulation is compromised may render these platelets

more thrombogenic. Due to the broader nature of PF4-cre recombination beyond the megakaryocyte lineage, low-level PF4-cre recombination may occur in circulating leukocytes, which may lead to the excision of the *Adcy6* gene in leukocytes [61-63]. While this may contribute to the thrombotic phenotype demonstrated in our AC6-KO mouse during *in vivo* thrombosis experiments, data regarding the expression of ACs and, in particular, AC6 in leukocytes is lacking [64, 65].

A general problem in studying AC biology is the lack of isoform-specific inhibitors or antibodies. This key issue is exemplified here where we were unable to precisely confirm the absence of AC6 through blotting and relied on RT-qPCR. Nevertheless, the genetic approach has allowed us for the first time to describe functional links between an AC isoform and the regulation of activation by an individual agonist. Given in our hands that only activation through PARs is affected, it suggests that AC6-generated cAMP is not linked to general G-protein coupled activation but is compartmentalised. In airway smooth muscle cells, AC2 and AC6 generate distinct pools of cAMP, suggesting that they may regulate different cellular responses in separate compartments [44, 66-68]. It is unclear if a similar model is present in platelets expressing AC5 and AC6, but there is evidence in cardiomyocytes for differential localisation [69]. This compartmentalisation occurs through the formation of macromolecular complexes with kinases and phosphodiesterases, coupled by A-kinase anchoring proteins (AKAPs). In cardiomyocytes, AC5 forms an AKAP scaffolded complex with the β AR, PKA and PDE4D3, from which AC6 is excluded, leading to AC5-specific actions. The role of AKAPS in platelet biology is unclear, although their presence is suggested by transcriptomic studies and our own work identifying the presence of AKAPs 7, 9, 12, 13, 79, 95, 149 and moesin (Khalil and Naseem, unpublished)[23, 24]. Of potential interest is AKAP9, which is an AC-associated AKAP [70, 71]. Previously, we have shown that AC5/6 is localised to lipid raft fractions in human platelets but were unable to determine if the two isoforms were in distinct lipid-enriched fractions or were co-localised [72]. It is possible that the colocalization of thrombin receptors with AC6 could account for our observations and open the possibility that partitioned pools of cAMP downstream of individual AC isoforms control specific aspects of platelet function in a coordinated manner. This may be a key area for understanding how cAMP and cGMP signalling pathways are coordinated to regulate platelet-driven haemostasis.

In summary, our study provides the first direct evidence that AC6, which is expressed in both mouse and human platelets at similar levels, plays a primary role in regulating haemostasis and thrombosis. Despite the presence of AC5 and soluble AC9 and their potential role in platelet cAMP generation, AC6 may be the key mediator of thrombosis in mice. The potential functional redundancy between AC5, AC6 and soluble AC9 in controlling platelet responses to specific agonists requires further investigation.

Authorship contributions:

BAW designed and performed experiments, analysed data, and wrote and edited the manuscript. MSH, JSK and LTC performed experiments, analysed data and edited the manuscript. CD analysed data and edited the manuscript. RAS, NAT and MTK provided essential materials and edited the manuscript. KMN designed the research, acquired the funding and wrote the manuscript.

Acknowledgements

This research was supported by the British Heart Foundation (FS/18/75/33978, PG/21/10819, PG/18/81/34110, & RG/F/22/110067). We want to thank the animal technicians and the Bioimaging and FACs facility staff at the University of Leeds for their support.

Conflict of Interest:

Nothing to declare.

Journal Pre-proof

References:

1. Astrup, T., *THE HAEMOSTATIC BALANCE*. Thrombosis Et Diathesis Haemorrhagica, 1958. **2**(3-4): p. 347-357.
2. Menter, D.G., et al., *Platelet "first responders" in wound response, cancer, and metastasis*. Cancer and Metastasis Reviews, 2017. **36**(2): p. 199-213.
3. Palmer, R.M.J., D.S. Ashton, and S. Moncada, *VASCULAR ENDOTHELIAL-CELLS SYNTHESIZE NITRIC-OXIDE FROM L-ARGININE*. Nature, 1988. **333**(6174): p. 664-666.
4. Radomski, Palmer, and Moncada, *ENDOGENOUS NITRIC-OXIDE INHIBITS HUMAN-PLATELET ADHESION TO VASCULAR ENDOTHELIUM*. Lancet, 1987. **2**(8567): p. 1057-1058.
5. Arnold, W.P., et al., *NITRIC-OXIDE ACTIVATES GUANYLATE CYCLASE AND INCREASES GUANOSINE 3'-5'-CYCLIC MONOPHOSPHATE LEVELS IN VARIOUS TISSUE PREPARATIONS*. Proceedings of the National Academy of Sciences of the United States of America, 1977. **74**(8): p. 3203-3207.
6. Moncada, S., *PROSTACYCLIN AND ARTERIAL-WALL BIOLOGY*. Arteriosclerosis, 1982. **2**(3): p. 193-207.
7. Moncada, S., et al., *ENZYME ISOLATED FROM ARTERIES TRANSFORMS PROSTAGLANDIN ENDOPEROXIDES TO AN UNSTABLE SUBSTANCE THAT INHIBITS PLATELET-AGGREGATION*. Nature, 1976. **263**(5579): p. 663-665.
8. Radomski, Palmer, and Moncada, *THE ANTI-AGGREGATING PROPERTIES OF VASCULAR ENDOTHELIUM - INTERACTIONS BETWEEN PROSTACYCLIN AND NITRIC-OXIDE*. British Journal of Pharmacology, 1987. **92**(3): p. 639-646.
9. Raslan and Naseem, *The control of blood platelets by cAMP signalling*. Biochemical Society Transactions, 2014. **42**: p. 289-294.
10. Fung, C.Y.E., et al., *Platelet Ca²⁺ responses coupled to glycoprotein VI and Toll-like receptors persist in the presence of endothelial-derived inhibitors: roles for secondary activation of P2X1 receptors and release from intracellular Ca²⁺ stores*. Blood, 2012. **119**(15): p. 3613-3621.
11. Rodan, G.A. and M.B. Feinstein, *INTERRELATIONSHIPS BETWEEN CA²⁺ AND ADENYLATE AND GUANYLATE CYCLASES IN CONTROL OF PLATELET SECRETION AND AGGREGATION*. Proceedings of the National Academy of Sciences of the United States of America, 1976. **73**(6): p. 1829-1833.
12. Shpakova, V., et al., *Potential and limitations of PKA/ PKG inhibitors for platelet studies*. Platelets, 2022. **33**(6): p. 859-868.
13. Kobayashi, T., et al., *Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice*. 2004. **114**(6): p. 784-794.
14. Cheng, Y., et al., *Role of prostacyclin in the cardiovascular response to thromboxane A2*. Science, 2002. **296**(5567): p. 539-41.
15. Berger, M., et al., *Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin: the role of phosphodiesterase 3A*. Haematologica, 2020. **105**(3): p. 808-819.
16. Ostrom, K.F., et al., *PHYSIOLOGICAL ROLES OF MAMMALIAN TRANSMEMBRANE ADENYLYL CYCLASE ISOFORMS*. Physiological Reviews, 2022. **102**(2): p. 815-857.
17. Skalhegg, B.S., et al., *Mutation of the C alpha subunit of PKA leads to growth retardation and sperm dysfunction*. Molecular Endocrinology, 2002. **16**(3): p. 630-639.
18. Huang, Y.Z., H. Roelink, and G.S. McKnight, *Protein kinase A deficiency causes axially localized neural tube defects in mice*. Journal of Biological Chemistry, 2002. **277**(22): p. 19889-19896.
19. Brandon, E.P., et al., *DERIVATION OF NOVEL EMBRYONIC STEM-CELL LINES AND TARGETING OF CYCLIC-AMP-DEPENDENT PROTEIN-KINASE GENES*. Recent Progress in Hormone Research, Vol 50: Proceedings of the 1993 Laurentian Hormone Conference, 1995. **50**: p. 403-408.
20. Imam, H., et al., *Impaired adenylyl cyclase signaling in acute myocardial ischemia: Impact on effectiveness of P2Y(12) receptor antagonists*. Thrombosis Research, 2019. **181**: p. 92-98.
21. Zeiler, M., M. Moser, and M. Mann, *Copy Number Analysis of the Murine Platelet Proteome Spanning the Complete Abundance Range*. Molecular & Cellular Proteomics, 2014. **13**(12): p. 3435-3445.
22. Balkenhol, J., et al., *Comparison of the central human and mouse platelet signaling cascade by systems biological analysis*. BMC Genomics, 2020. **21**(1): p. 897.

23. Burkhart, J.M., et al., *The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways*. Blood, 2012. **120**(15): p. E73-E82.
24. Rowley, J.W., et al., *Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes*. Blood, 2011. **118**(14): p. E101-E111.
25. Sim, D.S., et al., *Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels*. Blood, 2004. **103**(6): p. 2127-2134.
26. Hindle, M.S., et al., *Multidimensional flow cytometry reveals novel platelet subpopulations in response to prostacyclin*. Journal of thrombosis and haemostasis : JTH, 2021.
27. Spurgeon, B.E.J., et al., *Multiplexed phosphospecific flow cytometry enables large-scale signaling profiling and drug screening in blood platelets*. Journal of Thrombosis and Haemostasis, 2014. **12**(10): p. 1733-1743.
28. Duval, C., et al., *Elimination of fibrin gamma-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi*. Proceedings of the National Academy of Sciences of the United States of America, 2021. **118**(27).
29. Kobayashi, T., et al., *Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice*. J Clin Invest, 2004. **114**(6): p. 784-94.
30. Yang, J., et al., *Signaling through G(i) family members in platelets - Redundancy and specificity in the regulation of adenylyl cyclase and other effectors*. Journal of Biological Chemistry, 2002. **277**(48): p. 46035-46042.
31. Cheng, Y., et al., *Role of prostacyclin in the cardiovascular, response to thromboxane A2*. Faseb Journal, 2003. **17**(5): p. A1054-A1054.
32. Sabbatini, M.E., et al., *Adenylyl cyclase 6 mediates the action of cyclic AMP-dependent secretagogues in mouse pancreatic exocrine cells via protein kinase A pathway activation*. J Physiol, 2013. **591**(15): p. 3693-707.
33. Baldwin, T.A., et al., *Insights into the Regulatory Properties of Human Adenylyl Cyclase Type 9*. Mol Pharmacol, 2019. **95**(4): p. 349-360.
34. Vandeput, F., et al., *Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms*. Proceedings of the National Academy of Sciences of the United States of America, 2013. **110**(49): p. 19778-19783.
35. Hunter, R.W., C. MacKintosh, and I. Hers, *Protein Kinase C-mediated Phosphorylation and Activation of PDE3A Regulate cAMP Levels in Human Platelets*. Journal of Biological Chemistry, 2009. **284**(18): p. 12339-12348.
36. Feijge, M.A.H., et al., *Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3*. Biochemical Pharmacology, 2004. **67**(8): p. 1559-1567.
37. Smolenski, A., et al., *Analysis and Regulation of Vasodilator-stimulated Phosphoprotein Serine 239 Phosphorylation in Vitro and in Intact Cells Using a Phosphospecific Monoclonal Antibody*. Journal of Biological Chemistry, 1998. **273**(32): p. 20029-20035.
38. Ito, Y., et al., *Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats*. Scientific Reports, 2018. **8**(1).
39. Assinger, A., W. Schmid, and I. Volf, *Decreased VASP phosphorylation in platelets of male and female smokers of young age*. Platelets, 2010. **21**(8): p. 596-603.
40. Butt, E., et al., *CAMP-DEPENDENT AND CGMP-DEPENDENT PROTEIN-KINASE PHOSPHORYLATION SITES OF THE FOCAL ADHESION VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) IN-VITRO AND IN INTACT HUMAN PLATELETS*. Journal of Biological Chemistry, 1994. **269**(20): p. 14509-14517.
41. Reinhard, M., et al., *THE 46/50-KDA PHOSPHOPROTEIN VASP PURIFIED FROM HUMAN PLATELETS IS A NOVEL PROTEIN ASSOCIATED WITH ACTIN-FILAMENTS AND FOCAL CONTACTS*. Embo Journal, 1992. **11**(6): p. 2063-2070.
42. Moore, S.F., et al., *Opposing Roles of GSK3 α and GSK3 β Phosphorylation in Platelet Function and Thrombosis*. International Journal of Molecular Sciences, 2021. **22**(19): p. 10656.

43. Webb, J.G., et al., *Adenylyl cyclase isoforms and signal integration in models of vascular smooth muscle cells*. American Journal of Physiology-Heart and Circulatory Physiology, 2001. **281**(4): p. H1545-H1552.
44. Bogard, A.S., C. Xu, and R.S. Ostrom, *Human Bronchial Smooth Muscle Cells Express Adenylyl Cyclase Isoforms 2, 4, and 6 in Distinct Membrane Microdomains*. Journal of Pharmacology and Experimental Therapeutics, 2011. **337**(1): p. 209-217.
45. Nelson, C.P., et al., *Principal role of adenylyl cyclase 6 in K⁺ channel regulation and vasodilator signalling in vascular smooth muscle cells*. Cardiovascular Research, 2011. **91**(4): p. 694-702.
46. Gros, et al., *Adenylyl cyclase isoform-selective regulation of vascular smooth muscle proliferation and cytoskeletal reorganization*. Circulation Research, 2006. **99**(8): p. 845-852.
47. Gros, et al., *Regulation of vascular smooth muscle cell function by adenylyl cyclase isoforms*. Faseb Journal, 2006. **20**(5): p. A1117-A1117.
48. Hodges, G.J., et al., *Increased Blood Pressure and Hyperdynamic Cardiovascular Responses in Carriers of a Common Hyperfunctional Variant of Adenylyl Cyclase 6*. Journal of Pharmacology and Experimental Therapeutics, 2010. **335**(2): p. 451-457.
49. Bunday, R.A. and P.A. Insel, *Adenylyl cyclase 6 overexpression decreases the permeability of endothelial monolayers via preferential enhancement of prostacyclin receptor function*. Mol Pharmacol, 2006. **70**(5): p. 1700-7.
50. Heemskerk, J.W., et al., *Unravelling the different functions of protein kinase C isoforms in platelets*. FEBS Lett, 2011. **585**(12): p. 1711-6.
51. Hall, K.J., et al., *Genetic analysis of the role of protein kinase C θ in platelet function and thrombus formation*. PLoS One, 2008. **3**(9): p. e3277.
52. Pula, G., et al., *PKC δ regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation*. Blood, 2006. **108**(13): p. 4035-44.
53. Yacoub, D., et al., *Essential role of protein kinase C δ in platelet signaling, α IIb β 3 activation, and thromboxane A₂ release*. J Biol Chem, 2006. **281**(40): p. 30024-35.
54. Nagy, B., et al., *Impaired activation of platelets lacking protein kinase C- θ isoform*. Blood, 2009. **113**(11): p. 2557-67.
55. Hawiger, J., S. Parkinson, and S. Timmons, *Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets*. Nature, 1980. **283**(5743): p. 195-7.
56. Ichinohe, T., et al., *Cyclic AMP-insensitive activation of c-Src and Syk protein-tyrosine kinases through platelet membrane glycoprotein VI*. J Biol Chem, 1995. **270**(47): p. 28029-36.
57. Ichinohe, T., et al., *Cyclic AMP-insensitive Activation of c-Src and Syk Protein-tyrosine Kinases through Platelet Membrane Glycoprotein VI*. Journal of Biological Chemistry, 1995. **270**(47): p. 28029-28036.
58. Aburima, A., et al., *cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway*. Blood, 2013. **122**(20): p. 3533-3545.
59. Omar, M.H. and J.D. Scott, *AKAP Signaling Islands: Venues for Precision Pharmacology*. Trends in Pharmacological Sciences, 2020. **41**(12): p. 933-946.
60. Raslan, et al., *Targeting of type I protein kinase A to lipid rafts is required for platelet inhibition by the 3',5'-cyclic adenosine monophosphate-signaling pathway*. Journal of Thrombosis and Haemostasis, 2015. **13**(9): p. 1721-1734.
61. Tiedt, R., et al., *Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo*. Blood, 2007. **109**(4): p. 1503-1506.
62. Pertuy, F., et al., *Broader expression of the mouse platelet factor 4-cre transgene beyond the megakaryocyte lineage*. J Thromb Haemost, 2015. **13**(1): p. 115-25.
63. Nagy, Z., et al., *The Gp1ba-Cre transgenic mouse: a new model to delineate platelet and leukocyte functions*. Blood, 2019. **133**(4): p. 331-343.
64. Palmer, C., et al., *Cell-type specific gene expression profiles of leukocytes in human peripheral blood*. BMC Genomics, 2006. **7**: p. 115.
65. Forabosco, P., et al., *Transcriptome organization of white blood cells through gene co-expression network analysis in a large RNA-seq dataset*. Front Immunol, 2024. **15**: p. 1350111.

66. Liu, et al., *Adenylyl cyclase type 6 overexpression selectively enhances beta-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts*. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008. **377**(4-6): p. 359-369.
67. Ostrom, R.S., et al., *Selective enhancement of beta-adrenergic receptor signaling by overexpression of adenylyl cyclase type 6: Colocalization of receptor and adenylyl cyclase in caveolae of cardiac myocytes*. Molecular Pharmacology, 2000. **57**(5): p. 1075-1079.
68. Ostrom, et al., *Localization of adenylyl cyclase Isoforms and G protein-coupled receptors in vascular smooth muscle cells: Expression in caveolin-rich and noncaveolin domains*. Molecular Pharmacology, 2002. **62**(5): p. 983-992.
69. Timofeyev, V., et al., *Adenylyl Cyclase Subtype-Specific Compartmentalization Differential Regulation of L-Type Ca²⁺ Current in Ventricular Myocytes*. Circulation Research, 2013. **112**(12): p. 1567-+.
70. Raslan, Aburima, and Naseem, *The Spatiotemporal Regulation of cAMP Signaling in Blood Platelets-Old Friends and New Players*. Frontiers in Pharmacology, 2015. **6**.
71. Smolenski, A., *Novel roles of cAMP/cGMP-dependent signaling in platelets*. Journal of Thrombosis and Haemostasis, 2012. **10**(2): p. 167-176.
72. Raslan and Naseem, *Compartmentalisation of cAMP-dependent signalling in blood platelets: The role of lipid rafts and actin polymerisation*. Platelets, 2015. **26**(4): p. 349-357.

Figure Legends and Tables:**Figure 1: Confirmation of platelet-specific AC6-KO mouse.**

(A) Schematic representation of *Adcy6-lox* and *PF4-cre* constructs used in generating platelet-specific knockout (KO) of the *Adcy6* gene. The top construct, platelet factor 4 (PF4)-Cre contains a mouse PF4 promoter, an amino-terminal nuclear localisation sequence (NLS), a carboxy-terminal Myc epitope tag, iCre recombinase and a bovine growth hormone (BGH) PolyA sequence. The bottom construct is the floxed *Adcy6* gene with exons 3-12 (out of 21 exons) flanked by loxP sites and an FRT-flanked neomycin resistance gene. (B) mRNA expression of individual AC isoforms was analysed in washed platelets by RT-qPCR. Comparisons were made between WT and AC6-KO using an unpaired student's t-test with Welch's correction (means \pm SD, $n=3-4$, ** $p<0.01$, ns = not significant). (C) Total AC expression in washed platelets via immunoblot analysis with data presented as fold of gene of interest over GAPDH control. Representative blot image and densitometry relative to GAPDH control. Comparisons were made between WT and AC6-KO using an unpaired student's t-test with Welch's correction (means \pm SD, $n=4$, ** $p<0.01$).

Figure 2: Contribution of AC6 to platelet cAMP production.

(A) Washed platelets (2×10^8 platelets/mL) were treated with PGI_2 in increasing concentrations or (B) over time at fixed (100 nM) concentration. Reactions were terminated by 2.5% Dodecyltrimethylammonium Bromide and intracellular cAMP generation was monitored. Data expressed as the concentration of cAMP (fmol) per 1×10^7 platelets. Comparisons were made between WT and AC6-KO using two-way ANOVA with Šídák's multiple comparisons test (means \pm SD, $n=3$, ns=not significant, ** $p<0.01$ and **** $p<0.0001$). (C) Total PDE3A expression in washed platelets via immunoblot analysis relative to GAPDH control presented as representative blot image and densitometry. (D) Washed platelets were treated with and without milrinone (10 μM) and assessed for PDE3A activity using a luciferase-based kinetic assay and comparisons were made between WT and AC6-KO by a two-way ANOVA with Šídák's multiple comparisons test (means \pm SD, $n=3$, ns = not significant).

Figure 3: Contribution of AC6 to cAMP-mediated PKA phosphorylation events

(A – C) Washed platelets (5×10^8 platelets/mL) were treated with increasing concentrations of (A) PGI_2 (1 – 100 nM), (B) Fsk (0.1-10 μM) or (C) 8-CPT-cAMP (1-100 μM) before lysis with Laemmli buffer and separation of proteins via SDS-PAGE. Phosphorylation of individual PKA substrates ($\text{VASP}^{\text{Ser157}}$, $\text{pVASP}^{\text{Ser239}}$ and $\text{GSK3}\beta$) was assessed via immunoblotting. Data presented as (i) representative images and (ii – iv) densitometry analysis relative to appropriate loading control. Comparisons were made between WT and AC6-KO by a two-way ANOVA with Šídák's multiple comparisons test (means \pm SD, $n=3-5$, ns = not significant, * $p<0.05$, ** $p<0.01$ and **** $p<0.0001$). (D) Whole blood was treated with PGI_2 (0.1 – 100 nM) phospho $\text{VASP}^{\text{Ser157}}$, and phospho $\text{VASP}^{\text{Ser239}}$ was measured by phosphoflow cytometry. The extent of phosphorylation is shown by representative heatmaps and data expressed as fold-over basal from median fluorescence intensity (MFI) ($n=5$).

Figure 4: AC6 mediates inhibition of PAR4- but not CRP-XL-stimulated platelet activity.

(A) Whole blood was treated with CRP-XL (1 $\mu\text{g/mL}$) or (B) PAR4 peptide (100 μM) in the absence or presence of PGI_2 (1-100 nM) and incubated with fluorescently conjugated markers for platelet activation (CD62P and

JON/A) (n=5). (C) Whole blood was treated with CRP-XL (1 $\mu\text{g/mL}$) alone or in combination with PAR4 (100 μM) and incubated with AnnV (platelet marker for phosphatidylserine exposure) (n=3). Data expressed as percentage inhibition of median fluorescence intensity (MedianFI) and percentage inhibition of mean fluorescence intensity (MeanFI). Comparisons were made between WT and AC6-KO by two-way ANOVA with Šídák's multiple comparisons test (means \pm SD, ns = not significant, * $p < 0.05$, *** $p < 0.001$ and **** $p < 0.0001$). (D) Washed platelets (1×10^7 platelets/mL) were spread on fibrinogen (100 $\mu\text{g/mL}$) or collagen (50 $\mu\text{g/mL}$) for 30 min, washed twice with PBS to remove non-adherent platelets and then treated with PGI_2 (10 nM) for 2 min prior to fixation. Data presented as (i) representative images, (ii) average number of adhered platelets across eight images (FoV= 74.97 x 74.97 μm). Comparisons were made between absence and presence of PGI_2 for each group by two-way ANOVA with Tukey's multiple comparisons test (means \pm SD, n=4, ns = not significant, * $p < 0.05$, ** $p < 0.01$ and **** $p < 0.0001$). (E) Whole blood was perfused over fibrinogen (1 mg/mL) coated biochips at 1000s^{-1} in the presence and absence of PGI_2 (50 nM) for 2 minutes. Data presented as (i) representative images and (ii) percentage area covered. Comparisons were made between WT and AC6-KO using a two-way ANOVA with Šídák's multiple comparisons test (means \pm SD, n=5, ns = not significant, *** $p < 0.001$).

Figure 5: AC6 mediates haemostasis, thrombosis, and thrombus stability *ex vivo* and *in vivo*.

(A) To assess haemostasis, tail clip bleeding time assays were performed and compared using an unpaired student's t-test with Welch's correction (WT n=8, AC6-KO n=8, $p < 0.05$). (B – D) *In vivo* thrombus formation following FeCl_3 injury on mesenteric vessels of WT mice (n=8) was compared to AC6-KO mice (n=9). Data presented as (B) vessel occlusion time, (C) representative images, (D) (i) representative graph of thrombus area over time (D) (ii) percent thrombus area over time expressed as means \pm SD per mouse from an average of up to 2 vessels (WT n=8, AC6-KO n=9). Mean vessel occlusion time data were compared between WT and AC6-KO mice using an unpaired students t-test with Welch's correction (*** $p < 0.001$). Percentage thrombus size over time was compared between WT and AC6-KO mice using a two-way ANOVA with Šídák's multiple comparisons test (ns = not significant, * $p < 0.05$, *** $p < 0.001$ and **** $p < 0.0001$). (E) The percentage of reduction in the thrombus area was calculated for each vessel. Black bars indicate a percentage reduction in thrombus size greater than 15%, while the red line indicates the average percentage area for WT versus AC6-KO. Data presented as individual injuries per group (WT n=11 vessels from 8 mice, AC6-KO n=12 vessels from 9 mice). (F) Total number of embolic events was compared between WT and AC6-KO using an unpaired student's t-test with Welch's correction (* $p < 0.05$).

Table 1: Hematological parameters in WT and AC6-KO mice


Parameter	WT	AC6-KO	p-value
WBC ($10^9/L$)	4.36 ± 1.29	4.74 ± 1.24	0.66
RBC ($10^{12}/L$)	6.36 ± 0.32	6.35 ± 0.44	0.90
HGB (g/L)	91.40 ± 2.95	91.56 ± 4.61	0.65
HCT (%)	30.78 ± 1.27	30.84 ± 1.75	0.96
PLT ($10^9/L$)	402.50 ± 40.64	466.22 ± 138.00	0.50
MPV (fL)	6.59 ± 0.16	6.66 ± 0.10	0.27
LYMPH (%)	79.90 ± 2.07	76.00 ± 10.79	0.40
MXD (%)	8.09 ± 1.31	9.53 ± 4.13	0.32
NEUT (%)	12.01 ± 0.97	14.47 ± 6.95	0.46

RBC: red blood cells; HGB: haemoglobin, HCT: haematocrit; PLT: platelets; MPV: Mean Platelet Volume; WBC: white blood cells; LYM: lymphocytes; NEU: neutrophils; and MXD: mixed white blood cells.


*Data analysed by Mann–Whitney *U* test. WT $n=10$ and AC6-KO $n=9$.

Figure 1


A)




B) i)




B) ii)




B) iii)



B) iv)



C) i)



C) ii)




Figure 2




Figure 3 (updated)





Figure 4

Figure 5

